Nutriband Inc
NTRB
查看詳細走勢圖
4.490USD
-0.040-0.88%
收盤 12/19, 16:00（美東）報價延遲15分鐘
54.58M總市值
虧損本益比TTM
盤中分時
1分
30分
1小時
日k
週k
月k
日k
今天
-0.88%
5天
-11.96%
1月
-10.91%
6月
-42.36%
今年開始到現在
-4.67%
1年
+10.05%
查看詳細走勢圖
TradingKey Nutriband Inc股票評分
單位: USD 更新時間: 2025-12-19操作建議
Nutriband Inc當前公司基本面數據相對非常健康，增長潛力很大。當前估值合理，在醫療設備與耗材行業排名121/208位。機構持股佔比非常高，近一個月多位分析師給出公司評級為買入。最高目標價15.00。中期看，股價處於下降通道。近一個月，市場表現較差，但公司基本面和技術面得分較高。目前股價在壓力位和支撐位之間，可以做區間波段操作。
Nutriband Inc評分
壓力支撐
由於公司未披露，未能獲取相關數據
多維評測
本期評分
上期評分
分析師目標
基於
1
分析師
買入
評級
15.000
目標均價
+203.64%
漲幅空間
數據免責聲明：分析師評級與目標價由LSEG提供，僅供參考，不應當作投資建議
Nutriband Inc亮點
亮點風險
Nutriband Inc. is engaged in the development of a portfolio of transdermal pharmaceutical products. Its development pipeline consists of transdermal products that are based on proprietary AVERSA abuse-deterrent transdermal technology. Its lead product under development is AVERSA Fentanyl, an abuse deterrent fentanyl transdermal system that combines an approved generic fentanyl patch with its AVERSA abuse deterrent transdermal technology to reduce the abuse and misuse of fentanyl patches. Its development pipeline also includes AVERSA Buprenorphine and AVERSA Methylphenidate. It is developing a portfolio of transdermal pharmaceutical products to deliver already approved drugs or biologics that are typically delivered by injection but with the potential to improve compliance and therapeutic outcomes through transdermal delivery. AVERSA technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.
業績增長期
公司處於發展階段，最新年度總收入2.14M美元
利潤高增長
公司淨利潤處於行業前列，最新年度總收入2.14M美元
估值高估
公司最新PE估值-1.47，處於3年歷史高位
機構減倉
最新機構持股350.65K股，環比減少16.90%
先鋒集團持倉
明星投資者先鋒集團持倉，最新持倉202.74K股
活躍度增加
近期活躍度增加，過去20天平均換手率1.68
Nutriband Inc新聞
即將為您帶來更多新聞，敬請期待。 。 。
財務指標
每股收益
由於公司未披露，未能獲取相關數據
營業總收入
由於公司未披露，未能獲取相關數據
Nutriband Inc簡介
Nutriband Inc. is engaged in the development of a portfolio of transdermal pharmaceutical products. Its development pipeline consists of transdermal products that are based on proprietary AVERSA abuse-deterrent transdermal technology. Its lead product under development is AVERSA Fentanyl, an abuse deterrent fentanyl transdermal system that combines an approved generic fentanyl patch with its AVERSA abuse deterrent transdermal technology to reduce the abuse and misuse of fentanyl patches. Its development pipeline also includes AVERSA Buprenorphine and AVERSA Methylphenidate. It is developing a portfolio of transdermal pharmaceutical products to deliver already approved drugs or biologics that are typically delivered by injection but with the potential to improve compliance and therapeutic outcomes through transdermal delivery. AVERSA technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.
公司代碼NTRB
公司Nutriband Inc
CEOMelnik (Serguei)
網址https://nutriband.com/
常見問題
Nutriband Inc(NTRB)的當前股價是多少？
Nutriband Inc(NTRB)的當前股價是 4.490。
Nutriband Inc 的股票代碼是什麼？
Nutriband Inc的股票代碼是NTRB。
Nutriband Inc股票的52週最高點是多少？
Nutriband Inc股票的52週最高點是11.780。
Nutriband Inc股票的52週最低點是多少？
Nutriband Inc股票的52週最低點是3.722。
Nutriband Inc的市值是多少？
Nutriband Inc的市值是54.58M。
Nutriband Inc的淨利潤是多少？
Nutriband Inc的淨利潤為-10.48M。
現在Nutriband Inc(NTRB)的股票是買入、持有還是賣出？
根據分析師評級，Nutriband Inc(NTRB)的總體評級為買入，目標價格為15.000。
Nutriband Inc(NTRB)股票的每股收益（EPS TTM）是多少
Nutriband Inc(NTRB)股票的每股收益（EPS TTM）是-3.048。
相關品種
-0.24%
+0.25%
+0.87%
+1.88%
+0.22%
-0.55%
+0.53%
+0.12%
+1.35%
-0.10%
-1.23%
-0.77%
+0.10%
+0.46%
+0.46%
+0.97%
+0.59%
+0.23%
+0.45%
+1.74%
